Elsevier

Lung Cancer

Volume 84, Issue 1, April 2014, Pages 56-61
Lung Cancer

The effect of radical treatment and rehabilitation on muscle mass and strength: A randomized trial in stages I–III lung cancer patients

https://doi.org/10.1016/j.lungcan.2014.01.011 Get rights and content

Abstract

Objectives

Little is known about the impact of an oncological treatment on muscle mass and strength in patients with lung cancer and the impact of a subsequent rehabilitation program. This study investigates the effect of radical treatment and post-treatment pulmonary rehabilitation on muscle mass and strength in patients with lung cancer and the relationship between muscle mass and strength.

Methods

Lung cancer patients, candidate for radical treatment, were randomly (2:1) allocated after radical treatment to either standard follow up (CON) or a 12-week rehabilitation training program (RT). Muscle mass was estimated by bioelectric impedance and CT-scan. Muscle strength was estimated by measuring quadriceps force (QF) with a hand held dynamometer. All variables were measured before (M1) and after radical treatment (M2), and at the earliest 12 weeks after randomization (M3). Data are presented as means with standard deviation.

Results

45 lung cancer patients (age: 65 years (9)) participated in the study. At M2, both muscle cross sectional area (MCSA) and QF were significantly decreased (p < 0.05). 28 patients were randomized. 13/18 RT and 9/10 CON patients ended the trial. At M3, RT-patients improved significantly their MCSA compared to CON-patients (ΔMCSA: 6 cm2 (6) (p = 0.003) vs. 1 cm2 (11) (p = 0.8)).

Conclusion

Muscle mass and strength: (1) are decreased at presentation in a substantial part of lung cancer patients; (2) are significantly negatively affected by radical treatment and (3) completely recover after a 12 week structured rehabilitation program, whereas a further decline was observed in CON-patients.

Introduction

In cancer patients, muscle weakness the result of skeletal muscle wasting (loss of muscle mass) and decreased muscle strength [1] has been associated with increased morbidity [2], [3], excessive fatigue, reduced performance status, lack of energy [4], poor quality of life, poor treatment response and survival [5], [6]. Muscle mass is an even more accurate predictor of survival than BMI [7], [8], [9]. Cancer-related muscle wasting has been attributed to various mechanisms, such as the hypermetabolic status, caused by a direct effect of the tumor-induced secretion of hormones or cytokines [10] on the organism [11] and cancer-related fatigue (CRF) caused by the cancer-treatment and the reduced activity pattern [12]. However, the exact pathophysiological mechanism between muscle wasting, decreased muscle strength and CRF in cancer patients remains poorly understood [13].

Muscle wasting and decreased muscle strength are not systematically addressed in an oncological setting. Peripheral muscle mass and strength are regularly measured in COPD patients, since they are good markers of deconditioning and have been shown to respond to exercise training [8], [9]. Although muscle weakness is mostly observed in patients with advanced lung cancer, some degree may already be present at the time of diagnosis [14]. Little is known about the impact of an oncological treatment on muscle weakness in patients with lung cancer and the impact of a subsequent rehabilitation program. Preliminary data suggest that exercise may slow down the decline in muscle mass and physical functioning [15].

Several methods are available to assess muscle mass: dual energy X-ray absorptiometry (DEXA), midthigh computed tomography (mCT) and bioelectric impedance (BEI). The first two methods are very accurate and yield reproducible results, but are time consuming and expensive [16]. Moreover, mCT requires considerable expertise and exposes the patient to radiation [17], [18]. Conversely, BEI requires limited operator skills, is non-invasive and provides immediate results [16], but is less reliable in underweight or obese patients and in those with abnormal hydration status [19].

Current methods of strength testing include manual muscle testing, computerized dynamometry, and hand-held dynamometry. Although manual muscle testing is a practical option for strength testing, its questionable reliability and subjective nature has created an interest in alternative methods. The use of computerized dynamometry for measurement the isokinetic and isometric muscle strength has been shown to be highly reliable and is currently the gold standard for strength measures. However, their cost makes them uncommon in a clinical setting. Hand-held dynamometry is a relatively inexpensive and portable device, making it a practical alternative to computerized dynamometry. It has been shown to be reliable for evaluation of knee strength in various populations including patients with cancer [20].

The aim of the present study was to investigate the effect of a radical oncological treatment and of a 12-week rehabilitation program on muscle mass and strength in lung cancer patients. Secondary aims were determining the relationship between muscle mass and muscle strength and between muscle mass as measured by mCT and BEI.

Section snippets

Materials and methods

This study is a pre-defined sub study of REINFORCE [21], an open, prospective, randomized, controlled multicenter trial investigating the effects of rehabilitation in patients with either lung cancer or mesothelioma, treated with radical intent. Radical treatment was defined as either complete resection with or without a perioperative platinum-based chemo-(radio) therapy, or definitive thoracic radiotherapy with or without concurrent or sequential platinum-based induction chemotherapy. Patients

Results

Forty-five of the 121 patients included in the REINFORCE study participated in the present sub study (Fig. 1). Seventeen patients left the sub-study between inclusion (M1) and randomization (M2), because of lack of motivation (N = 6), disease progression (N = 5), comorbidities (N = 4) and ineligibility, because treatment did not induce a QF decrease of more than 10% (N = 2). Two patients did not undergo a mCT because of logistic reasons. Of the remaining 26 radically treated patients, 16 patients were

Discussion

The present study shows that muscle mass and muscle strength are significantly reduced in a substantial number of patients with lung cancer at presentation, and are further affected by an oncological treatment with radical intent. Moreover, the present data show that rehabilitation induces a significant recovery of quadriceps mass and strength.

It has been observed that muscle wasting is present in some patients at an early stage of cancer [26]. This study confirms this observation: baseline

Conclusion

The present study shows that a substantial number of lung cancer patients demonstrate a decreased muscle mass and strength at the time of diagnosis. Furthermore, it provides a scientific basis for the use of a structured rehabilitation program in radically treated patients with stages I–III lung cancer. It not only shows that radical treatment exerts negative effect on muscle mass and strength, but unequivocally demonstrates that rehabilitation has the potential to reverse these detrimental

Funding

This study was supported by the Belgian Government Agency of Innovation by Science and Technology for applied Biomedical Research and by the Clinical Research Fund of Ghent University Hospital, Belgium.

Conflict of interest statement

We declare no conflict of interest for all the authors and that the grant provider had no influence on the design and outcome of the study, nor on its analysis or content of this article.

Acknowledgements

The authors thank the members of the pulmonary rehabilitation team, Gilles Thysebaert and the patients for their gracious collaboration.

References (44)

  • L.W. Jones et al.

    Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction

    Lancet Oncol

    (2009)
  • C.M. Op den Kamp et al.

    Pre-cachexia in patients with stages I–III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system

    Lung Cancer

    (2012)
  • C.L. Granger et al.

    Exercise intervention to improve exercise capacity and health related quality of life for patients with non-small cell lung cancer: a systematic review

    Lung Cancer

    (2011)
  • G. Arbane et al.

    Evaluation of an early exercise intervention after thoracotomy for non-small cell lung cancer (NSCLC), effects on quality of life, muscle strength and exercise tolerance: randomised controlled trial

    Lung Cancer

    (2011)
  • K. Kisiel-Sajewicz et al.

    Lack of muscle contractile property changes at the time of perceived physical exhaustion suggests central mechanisms contributing to early motor task failure in patients with cancer-related fatigue

    J Pain Symptom Manage

    (2012)
  • E.W.H.M. Fredrix et al.

    Measurement of resting energy-expenditure in a clinical setting

    Clin Nutr

    (1990)
  • U.G. Kyle et al.

    Bioelectrical impedance analysis—Part I: Review of principles and methods

    Clin Nutr

    (2004)
  • J.M. Argiles et al.

    Muscle wasting in cancer and ageing: cachexia versus sarcopenia

    Adv Gerontol

    (2006)
  • S. Al-Majid et al.

    A biobehavioral model for the study of exercise interventions in cancer-related fatigue

    Biol Res Nurs

    (2009)
  • A. Vigano et al.

    Clinical survival predictors in patients with advanced cancer

    Arch Intern Med

    (2000)
  • C.M.M. Prado et al.

    Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity

    Clin Cancer Res

    (2007)
  • K. Marquis et al.

    Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease

    Am J Respir Crit Care Med

    (2002)
  • Cited by (24)

    • Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey

      2022, Lung Cancer
      Citation Excerpt :

      Although these percentages are not in accordance with the recent ACSM recommendations [13], they are in line with other studies reporting the oncologists’ lack of awareness about exercise guidelines [25,27]. Muscle wasting, sarcopenia, lack of strength, and cardiorespiratory fitness are recognized prognostic factors in patients with lung cancer [4,36,37] and these variables, are largely demonstrated to be improved by exercise [38,39], ideally as part of a multidisciplinary approach including nutrition and smoking cessation [40]. Whereas aerobic exercise is considered the major determinant to improve cardiorespiratory fitness, the strength component specifically acts on muscles, increasing their size and strength.

    • Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer

      2020, Annals of Oncology
      Citation Excerpt :

      Only two studies were identified in the setting of radical treatment (surgery or radiotherapy, with or without chemotherapy) for lung cancer. In the first study, 28 patients were randomly allocated after radical treatment to either standard follow-up or a 12-week rehabilitation training program.46 The study showed that muscle mass and strength are decreased at presentation in most patients and decline after radical treatment.

    • Exercise training for people following curative intent treatment for non-small cell lung cancer: a randomized controlled trial

      2017, Brazilian Journal of Physical Therapy
      Citation Excerpt :

      Similar to the current study, this earlier study was also likely to be underpowered to demonstrate a between-group difference in quadriceps force. A larger RCT (n = 45) of resistance exercise training for people in stage I to III lung cancer demonstrated significant between-group differences in quadriceps torque on completion of a 12-week training program.45 Of note, this RCT only included people who presented with quadriceps muscle weakness, defined as either a quadriceps muscle force < 70% of their predicted value or a decrement of 10% in quadriceps muscle force following lung cancer treatment.45

    • Physiotherapy management of lung cancer

      2016, Journal of Physiotherapy
      Citation Excerpt :

      The addition of the subsequently published trial60 to the meta-analysis continues to show no significant between-group difference for health-related quality of life (SMD 0.34, 95% CI –0.14 to 0.81) (Figure 2; see Figure 3 on the eAddenda for the detailed forest plot). Exercise following treatment with curative intent has also been researched in two randomised trials63,64 and a number of single-group studies.48,63 Exercise in this situation is also associated with improvements in functional capacity but not health-related quality of life.48

    View all citing articles on Scopus

    Clinical trial number: NCT00752700 .

    View full text